A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis - Study Results

A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis (ROSE)

This study is ongoing, but not recruiting participants.

Study NCT00531817 Information provided by Hoffmann-La Roche

First Received on September 18, 2007. Last Updated on August 3, 2010 History of Changes

Results First Received: July 6, 2010

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Investigator); Primary Purpose: Treatment
Condition:	Rheumatoid Arthritis
Interventions:	Drug: tocilizumab Drug: Placebo Drug: Permitted DMARDs

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Tocilizumab 8 mg/kg + DMARDs	Tocilizumab intravenously at a dose of 8 mg/kg over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
Placebo + DMARDs	Placebo IV over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.

Participant Flow: Overall Study

	Tocilizumab 8 mg/kg + DMARDs	Placebo + DMARDs
STARTED	412 ^[1]	207 ^[2]
COMPLETED	409	205
NOT COMPLETED	3	2

[1]	3 patients did not receive any study medication. Intent-to-treat population = 409.
[2]	2 patients did not receive any study medication. Intent-to-treat population = 205.

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Tocilizumab 8 mg/kg + DMARDs	Tocilizumab intravenously at a dose of 8 mg/kg over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
Placebo + DMARDs	Placebo IV over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.

Baseline Measures

	Tocilizumab 8 mg/kg + DMARDs	Placebo + DMARDs	Total
Number of Participants [units: participants]	412	207	619
Age ^[1] [units: years] Mean ± Standard Deviation	55.2 ± 12.06	55.8 ± 12.42	55.5 ± 12.24
Gender ^[1] [units: participants]
Female	325	172	497
Male	84	33	117

[1]	Intent-to-treat population: Tocilizumab 8 mg/kg + DMARDs: n = 409 Placebo + DMARDs: n = 205

Outcome Measures

Show All Outcome Measures

1. Primary:

Percentage of Patients With an ACR50 Response [ Time Frame: Week 24 ]

Show Outcome Measure 1

2. Secondary:

Percentage of Patients With ACR20 Response at Each Timepoint [ Time Frame: Week 4 ]

Show Outcome Measure 2

3. Secondary:

Percentage of Patients With ACR20 Response at Each Timepoint [ Time Frame: Week 8 ]

Show Outcome Measure 3

4. Secondary:

Percentage of Patients With ACR20 Response at Each Timepoint [ Time Frame: Week 12 ]

Show Outcome Measure 4

5. Secondary:

Percentage of Patients With ACR20 Response at Each Timepoint [ Time Frame: Week 16 ]

Show Outcome Measure 5

6. Secondary:

Percentage of Patients With ACR20 Response at Each Timepoint [ Time Frame: Week 20 ]

Show Outcome Measure 6

7. Secondary:

Percentage of Patients With ACR20 Response at Each Timepoint [ Time Frame: Week 24 ]

Show Outcome Measure 7

8. Secondary:

Percentage of Patients With ACR50 Response at Each Timepoint [ Time Frame: Week 4 ]

Show Outcome Measure 8

9. Secondary:

Percentage of Patients With ACR50 Response at Each Timepoint [ Time Frame: Week 8 ]

Show Outcome Measure 9

10. Secondary:

Percentage of Patients With ACR50 Response at Each Timepoint [ Time Frame: Week 12 ]

Show Outcome Measure 10

11. Secondary:

Percentage of Patients With ACR50 Response at Each Timepoint [ Time Frame: Week 16 ]

Show Outcome Measure 11

12. Secondary:

Percentage of Patients With ACR50 Response at Each Timepoint [ Time Frame: Week 20 ]

Show Outcome Measure 12

13. Secondary:

Percentage of Patients With ACR70 Response at Each Timepoint [ Time Frame: Week 4 ]

Show Outcome Measure 13

14. Secondary:

Percentage of Patients With ACR70 Response at Each Timepoint [ Time Frame: Week 8 ]

Show Outcome Measure 14

15. Secondary:

Percentage of Patients With ACR70 Response at Each Timepoint [ Time Frame: Week 12 ]

Show Outcome Measure 15

16. Secondary:

Percentage of Patients With ACR70 Response at Each Timepoint [ Time Frame: Week 16 ]

Show Outcome Measure 16

17. Secondary:

Percentage of Patients With ACR70 Response at Each Timepoint [ Time Frame: Week 20 ]

Show Outcome Measure 17

18. Secondary:

Percentage of Patients With ACR70 Response at Each Timepoint [ Time Frame: Week 24 ]

Show Outcome Measure 18

19. Secondary:

Mean Change From Baseline in Disease Activity Score 28 (DAS28) at Each Timepoint [ Time Frame: Week 4 ]

Show Outcome Measure 19

20. Secondary:

Mean Change From Baseline in Disease Activity Score 28 (DAS28) at Each Timepoint [ Time Frame: Week 8 ]

Show Outcome Measure 20

21. Secondary:

Mean Change From Baseline in Disease Activity Score 28 (DAS28) at Each Timepoint [ Time Frame: Week 12 ]

Show Outcome Measure 21

22. Secondary:

Mean Change From Baseline in Disease Activity Score 28 (DAS28) at Each Timepoint [ Time Frame: Week 16 ]

Show Outcome Measure 22

23. Secondary:

Mean Change From Baseline in Disease Activity Score 28 (DAS28) at Each Timepoint [ Time Frame: Week 20 ]

Show Outcome Measure 23

24. Secondary:

Mean Change From Baseline in Disease Activity Score 28 (DAS28) at Each Timepoint [ Time Frame: Week 24 ]

Show Outcome Measure 24

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
These results are based on a clinical data cut-off date of 30 June 2009.

Results Point of Contact:

Name/Title: Medical Communications
Organization: Hoffmann-La Roche
phone: 800-821-8590

No publications provided by Hoffmann-La Roche

Publications automatically indexed to this study:

Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, Kavanaugh A. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012 Feb;71(2):198-205. Epub 2011 Sep 26.

Responsible Party:	Disclosures Group, Hoffmann-La Roche
ClinicalTrials.gov Identifier:	NCT00531817 History of Changes
Other Study ID Numbers:	ML21136
Study First Received:	September 18, 2007
Results First Received:	July 6, 2010
Last Updated:	August 3, 2010
Health Authority:	United States: Food and Drug Administration